TLSI · NASDAQ
TriSalus Life Sciences, Inc.
$3.86 -0.05 (-1.28%)
Company overview
TriSalus Life Sciences, Inc., an immunotherapy company, develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- NASDAQ
- Market cap
- $238M
- Employees
- 110
- Headquarters
- Westminster, CO
- Website
- trisaluslifesci.com
- CEO
- Mary T. Szela
- Listed
- February 8, 2021
- P/E
- -2.74
- Dividend yield
- 0.00%
Company financials
- Revenue
- $44.9M
- Gross profit
- $38.2M
- Operating income
- -$28M
- EBITDA
- -$32.3M
- Net income
- -$27.3M
- EPS
- -$1.41
- Total assets
- $71M
- Total debt
- $34.5M
- Gross margin
- 85.07%
- Net margin
- -60.85%
- Earnings yield
- -36.53%
TLSI
1D
NASDAQ
O3.76H3.94L3.76C3.93+0.13 (+3.42%)Vol95.72K